Navegando por Palavras-chave "folic acid"
Agora exibindo 1 - 3 de 3
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosHomocysteine concentrations and molecular analysis in patients with congenital heart defects(Elsevier B.V., 2007-02-01) Galdieri, Luciano C.; Arrieta, Santiago R.; Silva, Celia M. C.; Pedra, Carlos A. C.; D'Almeida, Vania; Universidade Federal de São Paulo (UNIFESP); Inst Date Pazzanese CardiolBackground. Congenital heart defects are the result of incomplete heart development and, like many diseases, have been associated with high homocysteine concentration.Methods. We evaluated homocysteine, folic acid and vitamin B-12 concentrations, and the mutations 677C > T and 1298A > C in MTHFR, 844ins68 in CBS and 2756A > G in MTR genes in 58 patients with congenital heart defects, 38 control subjects, and mothers of 49 patients and 26 controls.Results. Control and patients presented normal range concentrations for homocysteine (7.66 +/- 3.16 mu M and 6.95 +/- 3.12 mu M, respectively), folic acid (8.31 +/- 3.00 ng/mL and 11.84 +/- 10.74 ng/mL) and vitamin B-12, (613.56 +/- 307.57 pg/mL and 623.37 +/- 303.12 pg/mL), which did not differ among groups. for the mothers studied, homocysteine and vitamin B-12 concentrations also did not differ between groups. However, folic acid concentrations of mothers showed significant difference, the highest values being in the group of patients. No difference was found in allele frequencies among all groups studied. Conclusions. in the studied groups, high homocysteine seems not to be correlated with congenital heart defects, as well as folic acid and vitamin B-12. the mutations studied, in isolation, were not related to congenital heart defects, but high concentration of maternal homocysteine is associated with the presence of three or four mutated alleles. (c) 2007 IMSS. Published by Elsevier Inc.
- ItemSomente MetadadadosSerum total homocysteine levels and the prevalence of folic acid deficiency and C677T mutation at the MTHFR gene in an indigenous population of Amazonia: The relationship of homocysteine with other cardiovascular risk factors(Int Soc Hypertension Blacks-ishib, 2004-12-01) Tavares, Edelweiss Fonseca [UNIFESP]; Vieira Filho, João Paulo Botelho [UNIFESP]; Andriolo, Adagmar [UNIFESP]; Perez, Ana Beatriz Alvarez [UNIFESP]; Vergani, Naja [UNIFESP]; Sanudo, Adriana [UNIFESP]; Gimeno, Suely Godoy Agostinho [UNIFESP]; Franco, Laercio Joel [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Hyperhomocysteinemia is a risk factor for cardiovascular disease. C677T mutation at the MTHFR gene and deficiencies of folic acid and vitamin B-12 may account for elevation of total homocysteine (tHcy). Ninety Brazilian Parka-teje Indians (90.0% of the population without admixture, aged greater than or equal to20 years) were studied. Hyperhomocysteinemia was observed in 26.7% of the Indians. No case of vitamin B-12 deficiency was detected. Folic acid deficiency was found in 43.3% of the subjects. Rates of mutated allele 677T and TT genotype were 40.7% and 14.0%, respectively. Prevalence of hypertension, dyslipidemia, smoking, WHIR greater than or equal to0.9, BMI greater than or equal to25 kg/m(2) and chronic alcohol use were 4.4%, 44.4%, 25.6%, 72.2%, 67.8%, and 0.0%, respectively. All creatinine values were normal. Natural logarithmic (In) tHcy showed no correlation with age, but was positively correlated with systolic (r=0.22) and diastolic (r=0.21) blood pressure and triglycerides (r=0.39) and inversely correlated with folic acid (r= -0.40) adjusted for age and sex. Total homocysteine (tHcy) was higher among TT genotype (P<.001). The multiple linear regression model, containing variables for sex, folic acid, TT genotype, and triglycerides, explained 50.0% of the variation of the In tHcy. in summary, high rates of cardiovascular risk factors were discovered. C667T mutation and folic acid deficiency can explain, at least in part, the observed hyperhomocysteinemia.
- ItemSomente MetadadadosSystemic Chemotherapy Interferes in Homocysteine Metabolism in Breast Cancer Patients(Wiley-Blackwell, 2014-03-01) Yamashita, Eliana K.; Teixeira, Bianca M.; Yoshihara, Renata N.; Kuniyoshi, Renata K.; Alves, Beatriz C. A.; Gehrke, Flavia S.; Vilas-Boas, Viviane A.; Correia, Joao A.; Azzalis, Ligia A. [UNIFESP]; Junqueira, Virginia B. C. [UNIFESP]; Pereira, Edimar Cristiano [UNIFESP]; Fonseca, Fernando L. A. [UNIFESP]; Universidade de São Paulo (USP); Universidade Federal de São Paulo (UNIFESP)BackgroundHyperhomocysteinemia in breast cancer (BC) patients can be a risk factor for thromboembolic events. This study aimed to evaluate homocysteine and its cofators (folic acid and vitamin B12) concentrations and platelet count at diagnosis of BC, 3 and 6 months after the beginning of chemotherapy treatment and to correlate them with clinical data.MethodsThirty-five BC patients were included; blood samples were obtained by venipuncture. Plasmatic Hcy and cofactors concentrations were measured by competitive chemiluminescent enzyme immunoassay method. Platelet count was done using an automated analyzer. Statistical analysis was performed using the software SPSS.ResultsDuring chemotherapy, homocysteine (P = 0.032) and vitamin B12 (P < 0.001) concentrations increased, while folate and platelets decreased (P < 0.001). Among the clinical data, the menopausal status showed significant positive correlation (P = 0.022) with homocysteine concentration increase.ConclusionsEvaluation of homocysteine concentrations during chemotherapy is extremely important because their levels increase during chemotherapy treatment, thus increasing the risk of thromboembolism development.